Cargando…

Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway

Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and subsequently revise a nurse led monitoring pathway for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Louise, Richardson, Amanda R. W., Holt, Richard C. L., Jones, Caroline A., Beresford, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250434/
https://www.ncbi.nlm.nih.gov/pubmed/22235302
http://dx.doi.org/10.1371/journal.pone.0029512
_version_ 1782220465132011520
author Watson, Louise
Richardson, Amanda R. W.
Holt, Richard C. L.
Jones, Caroline A.
Beresford, Michael W.
author_facet Watson, Louise
Richardson, Amanda R. W.
Holt, Richard C. L.
Jones, Caroline A.
Beresford, Michael W.
author_sort Watson, Louise
collection PubMed
description Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and subsequently revise a nurse led monitoring pathway for this condition. A cohort of 102 children presenting with HSP to a secondary/tertiary level UK paediatric hospital over a five year period, were monitored using a nurse led care pathway. Using this cohort, the incidence (6.21 cases per 100,000 children per year) and natural disease course of HSP nephritis (46% initial renal inflammation; 9% subsequent renal referral; 1% renal biopsy and immunosuppression) was determined. Older patients were at higher risk of requiring a renal referral (renal referral 12.3 (8.4–13.5) years vs. normal outcome 6.0 (3.7–8.5) years; p<0.01). A normal urinalysis on day 7 had a 97% (confidence interval 90 to 99%) negative predictive value in predicting a normal renal outcome. Using this data and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP. This is based on a six-month monitoring period for all patients presenting with HSP, which importantly prioritises patients according to the urine findings on day 7 and thus intensively monitors those at higher risk of developing nephritis. The pathway could be easily adapted for use in different settings and resources. The introduction of a standardised pathway for the monitoring of HSP will facilitate the implementation of disease registries to further our understanding of the condition and permit future clinical trials.
format Online
Article
Text
id pubmed-3250434
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32504342012-01-10 Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway Watson, Louise Richardson, Amanda R. W. Holt, Richard C. L. Jones, Caroline A. Beresford, Michael W. PLoS One Research Article Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and subsequently revise a nurse led monitoring pathway for this condition. A cohort of 102 children presenting with HSP to a secondary/tertiary level UK paediatric hospital over a five year period, were monitored using a nurse led care pathway. Using this cohort, the incidence (6.21 cases per 100,000 children per year) and natural disease course of HSP nephritis (46% initial renal inflammation; 9% subsequent renal referral; 1% renal biopsy and immunosuppression) was determined. Older patients were at higher risk of requiring a renal referral (renal referral 12.3 (8.4–13.5) years vs. normal outcome 6.0 (3.7–8.5) years; p<0.01). A normal urinalysis on day 7 had a 97% (confidence interval 90 to 99%) negative predictive value in predicting a normal renal outcome. Using this data and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP. This is based on a six-month monitoring period for all patients presenting with HSP, which importantly prioritises patients according to the urine findings on day 7 and thus intensively monitors those at higher risk of developing nephritis. The pathway could be easily adapted for use in different settings and resources. The introduction of a standardised pathway for the monitoring of HSP will facilitate the implementation of disease registries to further our understanding of the condition and permit future clinical trials. Public Library of Science 2012-01-03 /pmc/articles/PMC3250434/ /pubmed/22235302 http://dx.doi.org/10.1371/journal.pone.0029512 Text en Watson et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Watson, Louise
Richardson, Amanda R. W.
Holt, Richard C. L.
Jones, Caroline A.
Beresford, Michael W.
Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title_full Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title_fullStr Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title_full_unstemmed Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title_short Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway
title_sort henoch schonlein purpura – a 5-year review and proposed pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250434/
https://www.ncbi.nlm.nih.gov/pubmed/22235302
http://dx.doi.org/10.1371/journal.pone.0029512
work_keys_str_mv AT watsonlouise henochschonleinpurpuraa5yearreviewandproposedpathway
AT richardsonamandarw henochschonleinpurpuraa5yearreviewandproposedpathway
AT holtrichardcl henochschonleinpurpuraa5yearreviewandproposedpathway
AT jonescarolinea henochschonleinpurpuraa5yearreviewandproposedpathway
AT beresfordmichaelw henochschonleinpurpuraa5yearreviewandproposedpathway